Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018

SELL
$56.15 - $73.9 $15.8 Million - $20.8 Million
-281,600 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$47.85 - $70.45 $11.3 Million - $16.7 Million
236,524 Added 524.72%
281,600 $19 Million
Q1 2018

May 15, 2018

BUY
$51.15 - $61.0 $2.31 Million - $2.75 Million
45,076 New
45,076 $2.45 Million

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Point State Capital LP Portfolio

Follow Point State Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Point State Capital LP with notifications on news.